IN2014CN03333A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03333A
IN2014CN03333A IN3333CHN2014A IN2014CN03333A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A IN 3333CHN2014 A IN3333CHN2014 A IN 3333CHN2014A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A
Authority
IN
India
Prior art keywords
shk
potassium channel
inhibiting agent
modified
obesity
Prior art date
Application number
Other languages
English (en)
Inventor
George K Chandy
Sanjeev Kumar Upadhayay
Ping H Wang
Paolo Sassone Corsi
Kristin Lynn Eckel Mahan
Shawn Iadonato
Joseph Mukergee
Reza M Mirbolooki
Original Assignee
Univ California
Kineta One Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Kineta One Llc filed Critical Univ California
Publication of IN2014CN03333A publication Critical patent/IN2014CN03333A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN3333CHN2014 2011-10-03 2012-10-02 IN2014CN03333A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
PCT/US2012/058495 WO2013052507A1 (fr) 2011-10-03 2012-10-02 Traitement de l'obésité et de troubles liés à l'obésité par ciblage pharmacologique des canaux potassiques kv1.3

Publications (1)

Publication Number Publication Date
IN2014CN03333A true IN2014CN03333A (fr) 2015-07-03

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3333CHN2014 IN2014CN03333A (fr) 2011-10-03 2012-10-02

Country Status (16)

Country Link
US (2) US20150072940A1 (fr)
EP (1) EP2763702A4 (fr)
JP (1) JP2014531469A (fr)
KR (1) KR20140108518A (fr)
CN (1) CN103987408A (fr)
AU (1) AU2012318736A1 (fr)
BR (1) BR112014008065A2 (fr)
CA (1) CA2850357A1 (fr)
HK (1) HK1201048A1 (fr)
IL (1) IL231873A0 (fr)
IN (1) IN2014CN03333A (fr)
MX (1) MX2014004029A (fr)
RU (1) RU2014117558A (fr)
SG (1) SG11201401193XA (fr)
TW (1) TW201321403A (fr)
WO (1) WO2013052507A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072577B (zh) * 2004-10-07 2013-12-18 加利福尼亚大学董事会 ShK毒素类似物及其在选择性抑制Kv1.3钾通道中的应用
CN103687608B (zh) 2011-06-06 2018-06-26 奇尼塔一有限责任公司 基于shk的医药组合物以及其制备和使用方法
WO2013052507A1 (fr) 2011-10-03 2013-04-11 The Regents Of The University Of California Traitement de l'obésité et de troubles liés à l'obésité par ciblage pharmacologique des canaux potassiques kv1.3
US10265384B2 (en) * 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
TWI698438B (zh) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
TWI701249B (zh) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
AU5369798A (en) * 1996-11-27 1998-06-22 Bachem Bioscience, Inc. Shk toxin compositions and methods of use
WO1999013895A1 (fr) * 1997-09-17 1999-03-25 University Of Florida Nouvelles compositions de polypeptides inhibitrices de l'activite du canal potassium et leurs utilisations
JP3207823B2 (ja) 1999-04-28 2001-09-10 リノール油脂株式会社 共役リノール酸を有効成分とする褐色脂肪増加剤
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
CN101072577B (zh) 2004-10-07 2013-12-18 加利福尼亚大学董事会 ShK毒素类似物及其在选择性抑制Kv1.3钾通道中的应用
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP1928463A2 (fr) * 2005-08-17 2008-06-11 Solvay Pharmaceuticals GmbH Methode d'utilisation de composes inhibiteurs du canal du potassium
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
WO2013052507A1 (fr) 2011-10-03 2013-04-11 The Regents Of The University Of California Traitement de l'obésité et de troubles liés à l'obésité par ciblage pharmacologique des canaux potassiques kv1.3

Also Published As

Publication number Publication date
AU2012318736A1 (en) 2014-05-22
WO2013052507A1 (fr) 2013-04-11
KR20140108518A (ko) 2014-09-11
IL231873A0 (en) 2014-05-28
SG11201401193XA (en) 2014-05-29
HK1201048A1 (en) 2015-08-21
TW201321403A (zh) 2013-06-01
US20170095530A1 (en) 2017-04-06
JP2014531469A (ja) 2014-11-27
CN103987408A (zh) 2014-08-13
CA2850357A1 (fr) 2013-04-11
BR112014008065A2 (pt) 2019-09-24
US9878006B2 (en) 2018-01-30
MX2014004029A (es) 2014-08-01
EP2763702A1 (fr) 2014-08-13
RU2014117558A (ru) 2015-11-10
US20150072940A1 (en) 2015-03-12
EP2763702A4 (fr) 2015-04-15

Similar Documents

Publication Publication Date Title
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MY160894A (en) Oligosaccharide composition for treating skin diseases
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
IN2014CN03333A (fr)
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
WO2013169864A3 (fr) Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie
MX2013007189A (es) Metodos y composiciones adecuados para manejar glucosa en sangre en animales.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
MX2014001271A (es) Tratamiento de diabetes de tipo 2 con fty720.
UA61499U (en) massage mat
UA63764U (ru) Применение экстракта из листьев сныти обыкновенной в качестве лечебно-профилактического средства с гепатопротекторным действием